The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer

dc.contributor.authorMohamed S. Othman,
dc.contributor.authorMohamed Tharwat Elabbasy,
dc.contributor.authorAhmed M. Aref,
dc.contributor.authorAya A. Altaleb
dc.contributor.authorMarwa Hamdy Mohammed,
dc.contributor.authorDoaa Atef Mohamed Soliman,
dc.contributor.authorNashwa El-Khazragy,
dc.date.accessioned2024-11-06T13:16:37Z
dc.date.available2024-11-06T13:16:37Z
dc.date.issued2023-10
dc.descriptionmiRNA, micro-RNA; HER2-MBC, HER2-positive Metastatic Breast cancer; BC, breast cancer; BL, baseline; 1C, after completing Trastuzumab treatment; FOXP3, forkhead box P3; HER2, human epidermal growth factor receptor 2; TTP, time to progression; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; PASS, Power Analysis and Sample Size Software; ROC, Receiving operating characteristics curve; CI, 95% confidence interval; AUC, area under the curve.
dc.description.abstractPurpose: Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer (HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment response, no clinical studies have confirmed these results. Methods: The study involved 40 patients with HER2-positive metastatic breast cancer (HER2-MBC). The expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples at two time points: baseline (BL) and after the consent completion of one cycle of Trastuzumab, utilizing quantitative polymerase chain reaction (qPCR). Clinical response to Trastuzumab was evaluated 12 months post-therapy and correlated with the time to progression (TTP) through Kaplan-Meier analysis. Results: Low plasma expression level of miR-200c-3p was detected before therapy in HER2-MBC, compared to healthy controls, and decreased dramatically in the follow-up sample at disease progression, while increased after one cycle of Trastuzumab therapy in patients who were sensitive to Trastuzumab. At baseline, a low expression level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression. Conclusions: The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients.
dc.description.sponsorshipMSA University
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=13158&tip=sid&clean=0
dc.identifier.citationMSA Unversity
dc.identifier.doiDOI: 10.1177/15330338241292226
dc.identifier.urihttps://repository.msa.edu.eg/handle/123456789/6189
dc.language.isoen
dc.publisherSage: Technology in Cancer Research & Treatment
dc.relation.ispartofseries2 Technology in Cancer Research & Treatment; Volume 23: 1-10
dc.subjectTrastuzumab
dc.subjectHER2-positive breast cancer
dc.subjectmetastatic breast cancer
dc.subjectdrug resistance
dc.subjectmiR-200c
dc.subjectFOXP3
dc.subjectpredictor biomarker
dc.titleThe MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer
dc.typeArticle
person.affiliation.nameMSA University

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Bio 1.pdf
Size:
699.21 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: